Syngene International fell 1.63% to Rs 543.25 after the company reported 34.3% fall in consolidated net profit to Rs 84.10 crore on 11.8% rise in net sales to Rs 519.60 crore in Q2 FY21 over Q2 FY20.
Syngene's second quarter performance was primarily driven by good performance in the discovery services and dedicated R&D centre divisions.
The company commenced manufacturing of Remdesivir at its manufacturing facility in Bengaluru with initial distribution expected during the third quarter.
Meanwhile, credit ratings agency ICRA upgraded its credit rating in August from AA to AA+. "This is a further affirmation of Syngene's strong fundamentals and robust business model," the company said.
EBITDA in the second quarter increased by 6% to Rs 169 crore from Rs 160 crore reported in the same period last year. EBITDA was at 32% in Q2 FY21 as compared to 33% in Q2 FY20.
Profit before tax in Q2 September 2020 stood at Rs 94.20 crore, down by 44.6% from Rs 170.10 crore in Q2 September 2019. Current tax expense during the quarter tumbled 76% year-on-year (YoY) to Rs 10.10 crore.
Commenting on the results, Jonathan Hunt, managing director and chief executive officer - Syngene International, said: "The second quarter saw a positive return to growth following a muted first quarter that was impacted by COVID-19. This result reflects a robust operating performance as we have adapted to the COVID-19 situation. We are at near normal operating levels with all our scientists working on site with proper protective measures.
We expect to sustain our growth through the second half and are making good progress towards achieving our full year guidance."
Syngene International is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU